TriangleNCT00719901 · OUTCOME
Time to Progression (Phase II)
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- Time from registration to the time of progression
What was measured
The distribution of time to progression will be estimated using the method of Kaplan-Meier.
Analysis population: No participants proceeded to Phase II for evaluation.
Groups in this outcome
Treatment (Enzyme Inhibitor Therapy)
Patients receive obatoclax mesylate IV over 3 hours and bortezomib (1.3 mg/m\^2) IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| Treatment (Enzyme Inhibitor Therapy) | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- The distribution of time to progression will be estimated using the method of Kaplan-Meier.
- groups
- description
- Patients receive obatoclax mesylate IV over 3 hours and bortezomib (1.3 mg/m\^2) IV on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- Treatment (Enzyme Inhibitor Therapy)
- population Description
- No participants proceeded to Phase II for evaluation.
- reporting Status
- POSTED
- time Frame
- Time from registration to the time of progression
- title
- Time to Progression (Phase II)
- type
- SECONDARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice